Shaheen, Collins Issue Joint Statement On Sanofi's Decision To Reduce Insulin Prices
March 18, 2023
March 18, 2023
WASHINGTON, March 18 -- Sen. Jeanne Shaheen, D-New Hampshire, issued the following news release:
U.S. Senators Jeanne Shaheen (D-NH) and Susan Collins (R-ME), co-chairs of the Senate Diabetes Caucus, issued the following joint statement in response to drug maker Sanofi's announcement that it will cap insulin costs to $35 per month for individuals with private insurance and adjust the list price of Lantus - its most popular insulin - by 78 percent and its short-acting insulin Apidra . . .
U.S. Senators Jeanne Shaheen (D-NH) and Susan Collins (R-ME), co-chairs of the Senate Diabetes Caucus, issued the following joint statement in response to drug maker Sanofi's announcement that it will cap insulin costs to $35 per month for individuals with private insurance and adjust the list price of Lantus - its most popular insulin - by 78 percent and its short-acting insulin Apidra . . .